| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 14 | 2019 | 810 | 2.690 |
Why?
|
| Vancomycin | 10 | 2016 | 73 | 2.300 |
Why?
|
| Clostridium Infections | 10 | 2022 | 125 | 2.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 16 | 2023 | 923 | 1.920 |
Why?
|
| Antifungal Agents | 13 | 2020 | 125 | 1.860 |
Why?
|
| Enterocolitis, Pseudomembranous | 8 | 2019 | 52 | 1.850 |
Why?
|
| Herpes Zoster | 5 | 2019 | 79 | 1.780 |
Why?
|
| Triazoles | 10 | 2018 | 108 | 1.600 |
Why?
|
| Aminoglycosides | 7 | 2013 | 33 | 1.560 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2019 | 10 | 1.220 |
Why?
|
| Invasive Fungal Infections | 5 | 2020 | 10 | 1.210 |
Why?
|
| Antiviral Agents | 10 | 2021 | 497 | 1.170 |
Why?
|
| Nitriles | 5 | 2018 | 158 | 1.010 |
Why?
|
| Immunocompromised Host | 12 | 2021 | 145 | 1.000 |
Why?
|
| Pyridines | 6 | 2018 | 311 | 0.970 |
Why?
|
| Organophosphonates | 3 | 2018 | 52 | 0.780 |
Why?
|
| Cytosine | 3 | 2018 | 131 | 0.730 |
Why?
|
| Organ Transplantation | 3 | 2019 | 288 | 0.690 |
Why?
|
| Double-Blind Method | 15 | 2023 | 1756 | 0.670 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 153 | 0.610 |
Why?
|
| Mycoses | 3 | 2020 | 46 | 0.580 |
Why?
|
| Peptides, Cyclic | 2 | 2016 | 44 | 0.580 |
Why?
|
| Thiazoles | 2 | 2014 | 128 | 0.550 |
Why?
|
| Adenosine Monophosphate | 3 | 2021 | 29 | 0.540 |
Why?
|
| Lipopeptides | 2 | 2016 | 19 | 0.530 |
Why?
|
| Alanine | 3 | 2021 | 82 | 0.520 |
Why?
|
| Valine | 1 | 2016 | 60 | 0.520 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 40 | 0.520 |
Why?
|
| Drugs, Investigational | 1 | 2016 | 38 | 0.510 |
Why?
|
| Acyclovir | 1 | 2016 | 108 | 0.510 |
Why?
|
| Adult | 43 | 2022 | 27532 | 0.510 |
Why?
|
| Middle Aged | 39 | 2020 | 27030 | 0.480 |
Why?
|
| Aged | 29 | 2020 | 19943 | 0.480 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 174 | 0.480 |
Why?
|
| Transplant Recipients | 6 | 2023 | 152 | 0.450 |
Why?
|
| Male | 50 | 2020 | 43925 | 0.430 |
Why?
|
| Humans | 68 | 2024 | 92337 | 0.430 |
Why?
|
| Invasive Pulmonary Aspergillosis | 3 | 2018 | 8 | 0.420 |
Why?
|
| Daptomycin | 1 | 2013 | 3 | 0.420 |
Why?
|
| Minocycline | 1 | 2013 | 15 | 0.410 |
Why?
|
| Edetic Acid | 1 | 2013 | 42 | 0.410 |
Why?
|
| Treatment Outcome | 21 | 2020 | 8740 | 0.410 |
Why?
|
| Biofilms | 1 | 2013 | 47 | 0.400 |
Why?
|
| Female | 42 | 2020 | 47893 | 0.400 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1079 | 0.380 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 80 | 0.380 |
Why?
|
| Actinomycetales | 1 | 2011 | 5 | 0.370 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2011 | 16 | 0.370 |
Why?
|
| Neoplasms | 2 | 2019 | 3117 | 0.360 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2020 | 26 | 0.350 |
Why?
|
| Administration, Oral | 6 | 2018 | 673 | 0.350 |
Why?
|
| HIV Infections | 4 | 2013 | 895 | 0.350 |
Why?
|
| Ethanol | 1 | 2013 | 262 | 0.340 |
Why?
|
| Aged, 80 and over | 10 | 2018 | 6916 | 0.340 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 237 | 0.330 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 192 | 0.320 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 111 | 0.310 |
Why?
|
| Hematologic Neoplasms | 3 | 2020 | 355 | 0.300 |
Why?
|
| Administration, Intravenous | 5 | 2020 | 59 | 0.300 |
Why?
|
| Mucormycosis | 4 | 2018 | 18 | 0.280 |
Why?
|
| Young Adult | 9 | 2018 | 6624 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 887 | 0.260 |
Why?
|
| Acetates | 2 | 2017 | 69 | 0.250 |
Why?
|
| Diarrhea | 4 | 2015 | 180 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 328 | 0.240 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 313 | 0.240 |
Why?
|
| Adolescent | 13 | 2018 | 9504 | 0.240 |
Why?
|
| Legionellosis | 1 | 2024 | 6 | 0.230 |
Why?
|
| Quinazolines | 2 | 2017 | 214 | 0.230 |
Why?
|
| Legionella | 1 | 2024 | 16 | 0.230 |
Why?
|
| Vaccination | 2 | 2019 | 285 | 0.230 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 39 | 0.230 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 8 | 0.210 |
Why?
|
| Transplantation, Homologous | 4 | 2016 | 1015 | 0.210 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 50 | 0.210 |
Why?
|
| Cytomegalovirus | 3 | 2018 | 85 | 0.210 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 29 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 171 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 205 | 0.190 |
Why?
|
| Mycobacterium chelonae | 1 | 2021 | 4 | 0.180 |
Why?
|
| DNA, Viral | 3 | 2017 | 253 | 0.180 |
Why?
|
| Reaction Time | 2 | 1999 | 315 | 0.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 28 | 0.180 |
Why?
|
| Coronary Disease | 2 | 1995 | 262 | 0.180 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 20 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 269 | 0.170 |
Why?
|
| Drug Resistance, Viral | 2 | 2019 | 48 | 0.170 |
Why?
|
| Cardiomyopathies | 2 | 2017 | 272 | 0.170 |
Why?
|
| Anti-HIV Agents | 2 | 1999 | 173 | 0.170 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2022 | 72 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 866 | 0.160 |
Why?
|
| Injection Site Reaction | 1 | 2019 | 2 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1919 | 0.160 |
Why?
|
| Recurrence | 3 | 2017 | 1180 | 0.160 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.160 |
Why?
|
| Aminoimidazole Carboxamide | 2 | 1995 | 7 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2020 | 185 | 0.150 |
Why?
|
| Ribonucleosides | 2 | 1995 | 25 | 0.150 |
Why?
|
| Drug Therapy, Combination | 5 | 2011 | 807 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 202 | 0.150 |
Why?
|
| Neutrophils | 4 | 1999 | 323 | 0.150 |
Why?
|
| Psychomotor Performance | 3 | 2000 | 500 | 0.140 |
Why?
|
| Coinfection | 1 | 2018 | 63 | 0.140 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 158 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 98 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2017 | 92 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2018 | 1511 | 0.140 |
Why?
|
| Neutropenia | 1 | 2018 | 217 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 21 | 0.140 |
Why?
|
| Investigational New Drug Application | 1 | 2016 | 2 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2012 | 150 | 0.130 |
Why?
|
| Foscarnet | 1 | 2016 | 12 | 0.130 |
Why?
|
| Disease Management | 1 | 2019 | 340 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2368 | 0.130 |
Why?
|
| Zygomycosis | 2 | 2007 | 3 | 0.130 |
Why?
|
| Myocarditis | 1 | 2017 | 55 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 45 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 47 | 0.130 |
Why?
|
| Health Behavior | 1 | 2017 | 185 | 0.130 |
Why?
|
| Hepatitis B | 1 | 2016 | 79 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 82 | 0.120 |
Why?
|
| Mannans | 1 | 2015 | 5 | 0.120 |
Why?
|
| beta-Glucans | 1 | 2015 | 7 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2019 | 601 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 122 | 0.120 |
Why?
|
| Cognition | 1 | 1999 | 603 | 0.120 |
Why?
|
| Candida | 2 | 2012 | 18 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 366 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1995 | 174 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 60 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 996 | 0.110 |
Why?
|
| Vaccines, Attenuated | 1 | 2013 | 53 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 1995 | 233 | 0.110 |
Why?
|
| Aspergillus | 3 | 2018 | 9 | 0.100 |
Why?
|
| Histoplasmosis | 1 | 2013 | 27 | 0.100 |
Why?
|
| Clinical Medicine | 1 | 2013 | 34 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 77 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2013 | 206 | 0.100 |
Why?
|
| Amphotericin B | 2 | 2009 | 37 | 0.100 |
Why?
|
| Enterococcus | 1 | 2012 | 35 | 0.100 |
Why?
|
| HIV-1 | 3 | 1998 | 161 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2015 | 4468 | 0.100 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 868 | 0.090 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2011 | 104 | 0.090 |
Why?
|
| Microbiota | 1 | 2015 | 412 | 0.080 |
Why?
|
| Mucor | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cross Infection | 1 | 2011 | 153 | 0.080 |
Why?
|
| Fungi | 3 | 2018 | 67 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2021 | 9703 | 0.080 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 342 | 0.080 |
Why?
|
| Thromboxane-A Synthase | 1 | 1989 | 4 | 0.080 |
Why?
|
| Glycosides | 1 | 2008 | 21 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1989 | 95 | 0.070 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1989 | 59 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 153 | 0.070 |
Why?
|
| Arachidonic Acids | 1 | 1988 | 41 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 2003 | 424 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1999 | 78 | 0.070 |
Why?
|
| AIDS Dementia Complex | 2 | 1998 | 6 | 0.070 |
Why?
|
| Aspergillosis | 2 | 2018 | 39 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 815 | 0.070 |
Why?
|
| Feces | 3 | 2014 | 349 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2019 | 289 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2007 | 234 | 0.060 |
Why?
|
| Fungemia | 1 | 2005 | 15 | 0.060 |
Why?
|
| Child | 6 | 2022 | 7334 | 0.060 |
Why?
|
| Candidiasis | 1 | 2005 | 37 | 0.060 |
Why?
|
| United States | 4 | 2022 | 7348 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 907 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2005 | 138 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 3 | 1999 | 70 | 0.060 |
Why?
|
| Incidence | 3 | 2014 | 1661 | 0.060 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2004 | 52 | 0.060 |
Why?
|
| Hospitalization | 2 | 2020 | 927 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2007 | 378 | 0.060 |
Why?
|
| Pandemics | 2 | 2020 | 812 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1939 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 99 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2024 | 299 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 8 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 113 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2023 | 15 | 0.050 |
Why?
|
| Voriconazole | 2 | 2018 | 18 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 31 | 0.050 |
Why?
|
| Patient Isolation | 1 | 2003 | 14 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 115 | 0.050 |
Why?
|
| Disaster Planning | 1 | 2003 | 24 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2023 | 103 | 0.050 |
Why?
|
| Zidovudine | 2 | 1999 | 16 | 0.050 |
Why?
|
| HIV Seropositivity | 2 | 2000 | 52 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 1016 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 58 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 1994 | 43 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2001 | 11 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 460 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 33 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1999 | 167 | 0.050 |
Why?
|
| Secondary Prevention | 2 | 2013 | 172 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2001 | 74 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2013 | 3818 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2020 | 36 | 0.040 |
Why?
|
| Verbal Learning | 1 | 2000 | 30 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 65 | 0.040 |
Why?
|
| Respiratory System | 1 | 2020 | 119 | 0.040 |
Why?
|
| Zalcitabine | 1 | 1999 | 2 | 0.040 |
Why?
|
| Didanosine | 1 | 1999 | 2 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 1999 | 18 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 63 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2024 | 350 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1592 | 0.040 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
| Biomarkers | 2 | 2016 | 1850 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 305 | 0.040 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Infant | 3 | 2016 | 3218 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 36 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2018 | 110 | 0.040 |
Why?
|
| Phagocytes | 1 | 1998 | 14 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 694 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 220 | 0.040 |
Why?
|
| Mucorales | 1 | 2018 | 2 | 0.040 |
Why?
|
| Choice Behavior | 1 | 1999 | 163 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 1998 | 505 | 0.040 |
Why?
|
| Blood Platelets | 2 | 1989 | 148 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2018 | 71 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 247 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1999 | 498 | 0.040 |
Why?
|
| Allografts | 1 | 2018 | 197 | 0.040 |
Why?
|
| Dogs | 2 | 1995 | 705 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2019 | 224 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1194 | 0.030 |
Why?
|
| Memory Disorders | 1 | 1997 | 70 | 0.030 |
Why?
|
| Social Isolation | 1 | 2017 | 67 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 355 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2000 | 237 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 8 | 0.030 |
Why?
|
| Pilot Projects | 1 | 1999 | 900 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2016 | 24 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2016 | 16 | 0.030 |
Why?
|
| Parturition | 1 | 2016 | 23 | 0.030 |
Why?
|
| Lymphoma | 1 | 2018 | 267 | 0.030 |
Why?
|
| Femoral Vein | 1 | 2016 | 42 | 0.030 |
Why?
|
| Prognosis | 2 | 2015 | 3872 | 0.030 |
Why?
|
| Immunization | 1 | 2016 | 163 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2016 | 93 | 0.030 |
Why?
|
| Leukemia | 1 | 2018 | 321 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1181 | 0.030 |
Why?
|
| Enema | 1 | 2015 | 39 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5704 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2016 | 2517 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 148 | 0.030 |
Why?
|
| Galactose | 1 | 2015 | 33 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 902 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 376 | 0.030 |
Why?
|
| Mothers | 1 | 2016 | 149 | 0.030 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 1994 | 2 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1902 | 0.030 |
Why?
|
| Placenta | 1 | 2016 | 187 | 0.030 |
Why?
|
| Catalase | 1 | 1994 | 49 | 0.030 |
Why?
|
| Peroxidase | 1 | 1994 | 53 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1927 | 0.030 |
Why?
|
| Perfusion | 1 | 1995 | 261 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 368 | 0.030 |
Why?
|
| Mental Recall | 1 | 1995 | 166 | 0.030 |
Why?
|
| Animals | 5 | 2016 | 28003 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 1774 | 0.030 |
Why?
|
| Attention | 1 | 1998 | 403 | 0.030 |
Why?
|
| Apoptosis | 2 | 1999 | 1743 | 0.030 |
Why?
|
| Luminescent Measurements | 3 | 1999 | 62 | 0.030 |
Why?
|
| Arachidonic Acid | 2 | 1994 | 63 | 0.030 |
Why?
|
| Free Radicals | 2 | 1994 | 70 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2012 | 19 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 77 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 205 | 0.020 |
Why?
|
| Adenosine | 1 | 1994 | 250 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 923 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 75 | 0.020 |
Why?
|
| Neuropsychological Tests | 3 | 1998 | 523 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1239 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2729 | 0.020 |
Why?
|
| Phenylacetates | 1 | 1989 | 3 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 3509 | 0.020 |
Why?
|
| Rats, Inbred SHR | 1 | 1989 | 33 | 0.020 |
Why?
|
| Hydralazine | 1 | 1989 | 19 | 0.020 |
Why?
|
| Respiratory Burst | 2 | 1999 | 18 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 59 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1989 | 28 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 3110 | 0.020 |
Why?
|
| Benzazepines | 1 | 1989 | 65 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 312 | 0.020 |
Why?
|
| Eicosanoic Acids | 1 | 1988 | 2 | 0.020 |
Why?
|
| Lipoxygenase | 1 | 1988 | 8 | 0.020 |
Why?
|
| SRS-A | 1 | 1988 | 27 | 0.020 |
Why?
|
| Cell Communication | 1 | 1989 | 205 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1988 | 53 | 0.020 |
Why?
|
| Superoxides | 1 | 1988 | 76 | 0.020 |
Why?
|
| Serotonin | 1 | 1988 | 219 | 0.020 |
Why?
|
| Sulfonamides | 1 | 1989 | 328 | 0.020 |
Why?
|
| Echinocandins | 1 | 2005 | 5 | 0.020 |
Why?
|
| Internationality | 1 | 2005 | 71 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1989 | 909 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 211 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 206 | 0.010 |
Why?
|
| Kidney | 1 | 1989 | 1145 | 0.010 |
Why?
|
| Oxygen | 1 | 1988 | 763 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2004 | 291 | 0.010 |
Why?
|
| Rats | 1 | 1989 | 4067 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 1550 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 373 | 0.010 |
Why?
|
| Filgrastim | 1 | 1999 | 58 | 0.010 |
Why?
|
| Problem Solving | 1 | 1998 | 54 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1998 | 142 | 0.010 |
Why?
|
| Acridine Orange | 1 | 1996 | 2 | 0.010 |
Why?
|
| Ethidium | 1 | 1996 | 13 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 46 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1996 | 131 | 0.010 |
Why?
|
| Cell Size | 1 | 1996 | 71 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 509 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1995 | 13 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1996 | 441 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1995 | 62 | 0.010 |
Why?
|
| Adenosine Kinase | 1 | 1994 | 1 | 0.010 |
Why?
|
| Tubercidin | 1 | 1994 | 1 | 0.010 |
Why?
|
| Blood Physiological Phenomena | 1 | 1994 | 9 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1994 | 6 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1996 | 704 | 0.010 |
Why?
|
| Scintillation Counting | 1 | 1994 | 5 | 0.010 |
Why?
|
| Dipyridamole | 1 | 1994 | 14 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 1994 | 16 | 0.010 |
Why?
|
| Theophylline | 1 | 1994 | 34 | 0.010 |
Why?
|
| Plasma | 1 | 1994 | 51 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1994 | 21 | 0.010 |
Why?
|
| Cell Survival | 1 | 1996 | 1008 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 198 | 0.010 |
Why?
|
| Psychometrics | 1 | 1995 | 335 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1994 | 251 | 0.010 |
Why?
|
| Aspirin | 1 | 1994 | 163 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 1052 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1994 | 197 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1994 | 274 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1998 | 2978 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1994 | 466 | 0.010 |
Why?
|
| DNA | 1 | 1996 | 1308 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 2794 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1994 | 2448 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1994 | 1771 | 0.000 |
Why?
|